Boston Financial Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-2,679
Closed -$253K 352
2024
Q3
$253K Sell
2,679
-88
-3% -$36 0.01% 296
2024
Q2
$231K Sell
2,767
-4,588
-62% -$3.92K 0.01% 308
2024
Q1
$652K Sell
7,355
-2,130
-22% -$4.05K 0.02% 227
2023
Q4
$637K Buy
+9,485
New +$16.4K 0.02% 223

Other funds holding STLN

Boston Financial Management's STLN Position: Q4 2024 in Review

Boston Financial Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2024, closing a stake of 2,679 shares — an estimated $253K sold.

Boston Financial Management first reported a position in STLN in Q4 2023 and held it in 4 quarters. The position peaked at $652K in Q1 2024. 31 funds tracked by Wall St. Rank hold STLN as of Q4 2024.

  • Boston Financial Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Boston Financial Management sold 2,679 Starling Oncology Institute, Inc. Common Stock shares in Q4 2024, an estimated $253K.
  • Boston Financial Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2023 and held it in 4 quarters.
  • Boston Financial Management's Starling Oncology Institute, Inc. Common Stock position peaked at $652K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2024.

Based on Boston Financial Management's 13F filing for Q4 2024, filed 3 Feb 2025.